The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics
Abstract
PURPOSE: Endothelin receptors, particularly the ET A receptor, have been shown to participate in the pathophysiology of prostate and other cancers. Atrasentan, an endothelin antagonist, binds selectively to the ET A receptor. This study evaluated the safety, pharmacokinetics, and maximum-tolerated dose of atrasentan in cancer patients. PATIENTS AND METHODS: Patients who were 18 years or older and had histologically confirmed adenocarcinoma refractory to therapy enrolled in this 28-day, open-label, phase I study. Enrollment was planned for cohorts of three patients at doses escalating from 10 to 140 mg/d. When any patient had dose-limiting toxicity, that cohort was expanded. The primary outcome variable was safety; secondary outcome variables were pharmacokinetics, tumor response, and pain relief. RESULTS: Thirty-one cancer patients (14 prostate) were treated at daily atrasentan doses of 10, 20, 30, 45, 60, and 75 mg (n = 3 to 8 per cohort). The most common adverse events, such as rhinitis, headache, asthenia, and peripheral edema, were reversible on drug discontinuation and responded to symptom-specific treatment. Reversible hemodilution was apparent in laboratory findings and weight gain. Clinically significant headache was the dose-limiting adverse event; the maximum-tolerated dose was 60 mg/d. Pharmacokinetics were dose-proportional across the 10- to 75-mg dose range. Atrasentan was rapidly absorbed; the time to maximum observed concentration was approximately 1.5 hours. The terminal elimination half-life was approximately 24 hours, and steady-state plasma concentrations were achieved within 7 days. Decreases in prostate-specific antigen and pain relief were noted in a patient subset. CONCLUSION: Adverse events were consistent with atrasentan’s pharmacologic vasodilatory effect. Linear, dose-proportional pharmacokinetics suggest that atrasentan can be easily and consistently dosed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Price, D. D., Bush, F. M., Long, S., & Harkins, S. W. (1994) · Pain · doi:10.1016/0304-3959(94)90097-3 · Cited by 1,174
Cited by
The endothelin axis: emerging role in cancer
Nelson, J., Bagnato, A., Battistini, B., & Nisen, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc990 · Cited by 564
Self-citationCancer pain and its impact on diagnosis, survival and quality of life
Mantyh, P. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1914 · Cited by 441
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
Yin, J. J., Mohammad, K. S., Käkönen, S. M., Harris, S., Wu-Wong, J. R., Wessale, J. L., Padley, R. J., Garrett, I. R., Chirgwin, J. M., & Guise, T. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1830978100 · Cited by 381
Self-citationCarducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions. (2007) · Cancer · doi:10.1002/cncr.22996 · Cited by 294
Self-citationManagement of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Metadata
- Authors
- Carducci, M. A., Nelson, J. B., Kathy Bowling, M., Rogers, T., Eisenberger, M. A., Sinibaldi, V., Donehower, R., Leahy, T. L., Carr, R. A., Isaacson, J. D., Janus, T. J., Andre, A., Hosmane, B. S., & Padley, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-04-15
- Volume
- 20
- Issue
- 8
- Pages
- 2171-2180
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145939385
- Cited by
- 159
- References
- 2
- FWCI
- 15.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.